News | February 24, 2009

Researchers Work on PET with IMRT for "Dose Painting"

February 24, 2009 - Researchers are testing the use of positron emission tomography (PET) for dose painting, but have found the technique is limited by PET’s spatial resolution, according to researchers from the Catholic University of Louvain, Brussels, Belgium (Radiother. Oncol. doi: 10.1016/j.radonc.2008.11.014).

The theory is to use PET with a radiotherapy plan that takes account of tumor physiology, and to use PET to "paint" the dose to regions of intense activity or radiation resistance. PET is used in combination with intensity-modulated radiotherapy (IMRT) with an appropriate functional imaging modality.

The use of PET for dose painting relies on a perfect correlation between the observed PET signal and the underlying biology of interest. To test this, Nicolas Christian and colleagues imaged 15 tumor-bearing mice with PET following injection of the radiotracer 2-fluoro-2-deoxyglucose (18F-FDG). The mice were also imaged with MRI and then assessed using autoradiography.

The PET and autoradiography images however did not always match, particularly in tumor sub-volumes with high 18F-FDG-activity. This mismatch is significant because a biological image-guided IMRT plan would most likely increase the dose to these sites. The larger the tumor volume and the lower the activity threshold, then the better the match.

"Unfortunately, we do not yet have access to spatial image resolution that is good enough to be able to visualize what is going on at the microscopic level. We may make fairly large mistakes in the dose distribution by relying on what we see on the PET," said Vincent Grégoire, professor in radiation oncology at the Catholic University of Louvain and corresponding author for the paper.

Grégoire noted that if a PET system with a higher resolution were developed, the technique may be viable. The researchers are instead examining whether alternative radioisotope tracers could provide a better way of finding specific sites in the tumor where the dose should be increased, such as clusters of hypoxic cells. The researchers still want to investigate the concept of PET-based dose painting.

Source: Medical Physics Web

For more information: medicalphysicsweb.org

Related Content

Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
PET Imaging Agent Could Provide Early Diagnosis of Rheumatoid Arthritis

Coronal 18F-FEDAC PET/CT section of a mouse with collagen-induced arthritis. (A) On day 23 and day 37, increased uptake is noted in the front and hind paws of this mouse with collagen-induced arthritis. (B) Predictive performance of day 23 18F-FEDAC uptake for the development of clinical arthritis. ROC = receiver operating characteristic; Sn = sensitivity; Sp = specificity. Credit: Seoul National University and Ewha Womans University, Seoul, South Korea

News | PET Imaging | May 17, 2018
A novel positron emission tomography (PET) tracer developed by Korean researchers can visualize joint inflammation and...
PET Imaging Shows Protein Clumping May Contribute to Heart Failure Development
News | PET Imaging | May 11, 2018
A team led by Johns Hopkins University Researchers has discovered that protein clumps appear to accumulate in the...
Overlay Init